What follow‑up plan should be used for an adult ADHD patient taking Strattera (atomoxetine) 60 mg daily?

Follow-Up Plan for Adult ADHD Patient on Strattera 60mg Daily

For an adult ADHD patient on Strattera (atomoxetine) 60mg daily, schedule monthly follow-up appointments until symptoms are stabilized, then extend to every 2-3 months for maintenance monitoring. This patient is currently on a suboptimal dose and likely requires titration to the target dose of 80-100mg daily for maximum therapeutic benefit 1, 2.

Immediate Assessment Priorities

Dose Optimization

• The current 60mg dose is below the recommended target range. Real-world data show that adults frequently receive an average dose of only 60mg/day, when the FDA-approved target dose is 80mg/day with a range of 60-120mg/day 1, 2.
• Titrate to 80mg daily if tolerated, as studies demonstrate that effect sizes increase substantially at target dose (0.82 effect size at 80mg vs lower doses) 3.
• Maintain the target dose for 4-6 weeks before judging efficacy, as atomoxetine shows increasing effectiveness over time, with moderate effect sizes emerging only after 6 months of treatment at target dose 2, 3.

Symptom Monitoring at Each Visit

Use standardized rating scales to objectively track response:

• Conners' Adult ADHD Rating Scale (CAARS) - primary measure for ADHD symptom severity 1, 4
• Adult ADHD Investigator Symptom Rating Scale (AISRS) - tracks both inattentive and hyperactive/impulsive symptoms 3, 4
• Self-ratings from the patient are essential for adults 5

Assess specific target symptoms:

• Inattention, hyperactivity, and impulsivity across different settings (work, home, social)
• Evening symptom control, as once-daily morning dosing provides coverage through evening hours 4
• Executive functioning improvements using validated tools like BRIEF-A 6

Side Effect Surveillance

Systematically assess common adverse events by asking specific questions 5:

Early-onset side effects (typically appear within week 1) 7:

• Nausea (median resolution: 3-53 days)
• Dry mouth
• Decreased appetite
• Fatigue
• Insomnia
• Headaches

Monitor at every visit:

• Blood pressure and heart rate - atomoxetine causes modest increases that reverse upon discontinuation 7
• Weight - provides objective measure of appetite effects 5
• Urinary hesitation - particularly in males 4
• Sexual dysfunction in males - can have lingering resolution times 7, 4

Visit Schedule Algorithm

During Dose Titration Phase (Weeks 1-6)

• Weekly contact (can be by telephone) during dose adjustments 5
• If increasing from 60mg to 80mg, schedule follow-up at 1 week to assess tolerability
• If further titration to 100mg is needed, maintain weekly contact

Stabilization Phase (Months 2-6)

• Monthly appointments until symptoms are stabilized 5
• Symptoms are considered stabilized when patient achieves consistent improvement with minimal side effects
• Continue monthly visits if there are:
  • Persistent side effects requiring management
  • Comorbid psychiatric conditions
  • Adherence concerns
  • Need for ongoing psychoeducation

Maintenance Phase (After 6 months)

• Every 2-3 months once stable response is achieved
• More frequent visits if:
  • Treatment response weakens
  • New side effects emerge
  • Life circumstances change significantly
  • Comorbid conditions require attention

Critical Clinical Considerations

Common Pitfalls to Avoid

1. Premature discontinuation due to "lack of efficacy" - Atomoxetine requires 4-6 weeks at target dose to judge effectiveness, with continued improvement up to 6 months 2, 3. Don't abandon treatment too early.

2. Underdosing - The 60mg dose is subtherapeutic for most adults. Real-world underdosing is associated with poor outcomes 2.

3. Inadequate side effect management - Most side effects appear early and resolve within 3-53 days. Dose timing adjustments or temporary dose reduction can help patients tolerate titration 7.

4. Failure to set appropriate expectations - Inform patients that full therapeutic effect develops gradually over months, not weeks 2, 3.

Safety Monitoring

Contraindications to verify:

• Not using MAO inhibitors (absolute contraindication) 5
• No severe hepatic impairment (dose adjustment required for moderate/severe hepatic insufficiency) 1
• Screen for psychosis, which is a true contraindication 5

Psychiatric monitoring:

• Assess for suicidal ideation, anxiety, agitation, mood changes at every visit, particularly during early treatment and dose adjustments 1
• Atomoxetine does not worsen anxiety in patients with comorbid anxiety disorders 1

Adherence and Psychoeducation

• Discuss medication adherence at each visit - once-daily morning dosing improves compliance 4
• Provide reading materials about ADHD and atomoxetine 5
• Address functional impairment in work, relationships, and daily activities
• Consider adjunctive psychosocial interventions if medication alone provides insufficient benefit

Long-term Maintenance Considerations

• No tolerance develops to atomoxetine's therapeutic effects 5
• Maintenance treatment prevents relapse - studies show significantly longer time to relapse with continued treatment versus placebo 1
• Executive function improvements are maintained during continued treatment and may persist for up to 6 months after discontinuation 6